Abstracts
Showing 851 abstracts.
Citation
R Kreitchmann, A Stek, B Best, E Capparelli, J Wang, DE Shapiro, N Chakhtoura, S Burchett, M Mirochnick. Interaction between etonogestrel-releasing implant and 3 antiretroviral regimens. Presented at: CROI 2017; 2017 Feb 14.Conference
CROI 2017
Study
P1026S
Citation
A Weinberg, JC Lindsey, R Bosch, D Persaud, P Sato, B Heckman, K Richardson, A Zadzilka, M Nelson, MJ Levin. B and T cell subsets and immunogenicity of rotavirus vaccine in PHIV and PHEU Infants. Presented at: CROI 2017; 2017 Feb 15.Conference
CROI 2017
Study
P1072
Citation
VS Opollo, X Wu, R Lando, S Swindells, A Gupta, A Hesseling, R Dawson, MD Hughes, S Shah. HIV testing uptake among household contacts of MDR-TB index cases in eight countries. Presented at: CROI 2017; 2017 Feb 15.Conference
CROI 2017
Study
IMPAACT 2003/ACTG 5300
Citation
K Rough, GR Seage III, PL Williams, S Hernandez-Diaz, Y Huo, EG Chadwick, RM Hoffman, E Barr, ED Shapiro, K Patel. TDF/FTC in pregnancy shows no increase in adverse infant birth outcomes in US cohorts. Presented at: CROI 2017; 2017 Feb 16.Conference
CROI 2017
Citation
B Chi, M McFarland, M Owor, T Chipato, M Qin, S Dadabhia, D Gnanashanmugam, N Chakhtoura, MG Fowler, JS Stringer. Antenatal antiretroviral therapy and adverse birth outcomes: the PROMISE trial. Presented at: CROI 2017; 2017 Feb 16.Conference
CROI 2017
Study
1077BF, 1077FF
Citation
D Sebikari, M Qin, M Owor, J Stringer, M Farhad, N Chakhtoura, B Chi, K Klingman, G Theron, MG Fowler. Risk factors for low birth weight and preterm delivery in the PROMISE trial. Presented at: CROI 2017; 2017 Feb 16.Conference
CROI 2017
Study
1077BF, 1077FF
Citation
JH Pilotto, S Brummel, RM Hoffman, P Britto, G Masheto, L Aurpibul, N Chakhtoura, K Klingman, JS Currier. Subsequent pregnancy outcomes in women during follow-up in PROMISE 1077HS. Presented at: CROI 2017; 2017 Feb 16.Conference
CROI 2017
Study
1077HS
Citation
N Hanan, M Paul, Y Huo, E Capparelli, S Kapetanovic, JL Ariansen, E Smith, P Brouwers, B Best. Sertraline pharmacokinetics in HIV-infected on ARV and uninfected youth. Presented at: CROI 2017; 2017 Feb 16.Conference
CROI 2017
Study
P1080
Citation
T Ruel, E Acosta, RP Singh, C Alvero, K George, S Popson, C Vavro, R Hazra, A Wiznia. Dolutegravir pharmacokinetics, safety and efficacy in HIV+ children 2 to 6 years old. Presented at: CROI 2017; 2017 Feb 16.Conference
CROI 2017
Study
P1093
Citation
A Bekker, A Violari, M Cababasay, J Wang, L Wienser, E Capparelli, M Cotton, F Nakwa, M Mirochnick. Pharmacokinetics of nevirapine prophylaxis in HIV-exposed low birth weight infants. Presented at: CROI 2017; 2017 Feb 16.Conference
CROI 2017
Study
P1106